脑尔新胶嚢治疗精神分裂症的初步临床观察

Clinical Effect of Naoerxin Capsule on the Treatment of Schizophrenia

目的探讨脑尔新胶囊治疗精神分裂症的临床疗效。方法将中医辨证为狂病,痰火扰神证的偏执型、未分化型精神分裂症患者64例随机分为脑尔新胶囊观察组和利培酮对照组各32例,疗程6周。观察比较两组治疗前后阴性症状和阳性症状量表(PANSS)评分的变化、临床疗效及副反应量表(TESS)评分。结果治疗后两组PANSS评分均较治疗前显著下降(P<0.01),组间比较差异无统计学意义(P>0.05);观察组总有效率为80.0%,对照组为83.3%,两组差异无统计学意义(P>0.05);观察组TESS评分明显低于对照组(P<0.05)。结论脑尔新胶囊治疗首发偏执型精神分裂症疗效确切,副反应发生率低,耐受性较好。

Objective To assess the efficacy of Naoerxin capsule in the treatment of schizophrenia. Methods 64 patients with madness, Tanhuo Shaoshen type paranoid and undifferentiated schizophrenia were randomly assigned to the observation group（Naoerxin capsule） and control group（risperidone）, 32 patients in each group, and the curse was for 6weeks. The changes in PANSS score, clinical effect, TESS score were observed before and after the treatment. Results The PANSS score were reduced significantly after treatment（P〈0.01）. The treatment effect had no significant differences between two groups（P〉.05）. The total effective rate was 80.00% in the observation group, and 83.33% in the control group. There was no significant difference between the two groups（P〉0.05）. The TESS score in the observation group was lower obviously than the control group（P〉0.05）. Conclusion Naoerxin capsule showed good effect in treatment of newly diagnosed paranoid schizophrenia. The drug displayed low adverse effect rate and was well tolerated.